Definite | $10,000,000 | (Aug 22, 2025)
WALLROUND | $4,873,008 | (Aug 22, 2025)
Method AI | $20,000,000 | (Aug 22, 2025)
Actithera
Norway
- Oslo
- 09/07/2025
- Series A
- $75,500,000
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.
- Industry Biotechnology Research
- Website https://actithera.com/
- LinkedIn https://www.linkedin.com/company/actithera/
Related People
Andreas GoutopoulosFounder
United States -
Boston, Massachusetts
Founder of Actithera, developing smarter radiopharmaceuticals to treat cancer more effectively and safely. Focused on turning chemistry and science into better outcomes for patients.
Therm | $3,600,000 | (Aug 22, 2025)
SugaROx | $1,341,635 | (Aug 22, 2025)
Molecular You | $5,000,000 | (Aug 22, 2025)
Verdata | $8,000,000 | (Aug 22, 2025)
Agenda Hero | $5,600,000 | (Aug 22, 2025)
The Better Meat Co. | $31,000,000 | (Aug 22, 2025)
CLIKA Inc. | Undisclosed Amount | (Aug 22, 2025)
Grid Aero | $6,000,000 | (Aug 22, 2025)
CVector | $1,500,000 | (Aug 22, 2025)